Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.

@article{Hiatt2002PreventingAE,
  title={Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.},
  author={William R Hiatt},
  journal={Journal of internal medicine},
  year={2002},
  volume={251 3},
  pages={
          193-206
        }
}
Patients with peripheral arterial disease (PAD) are at increased risk of generalized atherothrombotic events. Epidemiologic data shows a high rate of co-prevalence of PAD and atherosclerosis in other vascular beds. Aggressive risk-factor modification and antiplatelet therapy has become the cornerstone of treatment to prevent ischaemic events associated with PAD. Recent clinical trials have confirmed the clinical benefit of clopidogrel and ticlopidine in patients with PAD, agents that… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

The Effect of a Loading Dose (300 mg) of Clopidogrel on Platelet Function in Patients with Peripheral Arterial Disease

  • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2003
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Insufficient modification of atherosclerosis risk factors in PAD patients.

  • Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  • 2018